Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 5:24 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 5:24 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead
Five Major Myths about Options Trading
by David Bartosiak
These are the five biggest myths about options trading
Falling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD)
by Zacks Equity Research
Gilead Sciences (GILD) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data
by Arpita Dutt
Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.
Gilead (GILD) Announces Data on Combination Therapy for HIV
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) recently announced positive data from a phase II study on HIV cocktail therapy.
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More
by Zacks Equity Research
The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.
Forget Gilead, Buy These 5 Biotech Stocks Instead
by Arpita Dutt
With Gilead (GILD) providing a not-so-rosy outlook for 2017 as its HCV franchise continues to face challenges, here's a look at 5 biotech stocks that look better-positioned.
Biotech ETFs Powered by Q4 Earnings
by Sweta Killa
Improved earnings are driving the biotech space and ETFs higher over the past 10 days.
Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints
by Zacks Equity Research
Gilead Sciences' (GILD) fourth quarter results beat on both earnings and sales but the guidance for 2017 was quite disappointing.
Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib
by Arpita Dutt
Although both Amgen (AMGN) and Gilead reported better-than-expected 4Q results, the companies provided a disappointing sales outlook for 2017.
Healthcare Stocks: The Buying Opportunity of the Year?
by Tracey Ryniec
Tracey and Kevin discuss whether healthcare stocks are still the ???sure things??? they???ve been the last 10 years.
Gilead Sciences Posts Q4 Earnings Beat, Slumps on Weak Guidance
by Madeleine Johnson
Gilead Sciences Inc. (GILD) just released its fourth quarter fiscal 2016 financial results, posting earnings, before non-recurring items, of $2.64 cents per share and revenues of $7.3 billion
Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Gilead Sciences Inc. (GILD ) is scheduled to report fourth-quarter 2016 results on Feb 7, after the market closes.
Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline
by Arpita Dutt
2017 will be a year of significant R&D investment for AbbVie (ABBV) as well as several late-stage readouts which will give an insight into the company's long term growth prospects.
Biotech Stock Roundup: Synergy Drug Gets FDA Nod, AbbVie, GILD HCV Drugs under EU Review
by Arpita Dutt
There were quite a few updates on the regulatory front this week in the biotech sector including FDA approval for Synergy's (SGYP) drug.
Gilead (GILD) HCV Therapy Application Validated in Europe
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that its MAA for once-daily, single tablet regimen of Sovaldi, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for HCV treatment has been fully validated.
Is Gilead Sciences (GILD) a Great Stock for Value Investors?
by Zacks Equity Research
Let's delve into the value metrics of Gilead Sciences (GILD) and determine whether it is a good value investment right now.
The Zacks Analyst Blog Highlights: Gilead Sciences, Las Vegas Sands, Illinois Tool Works, Pfizer and Lockheed Martin
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Las Vegas Sands, Illinois Tool Works, Pfizer and Lockheed Martin
4 Top Biotech Mutual Funds for 2017
by Zacks Equity Research
Biotechnology shares have welcomed this year in style, marking a striking reversal from last year???s dismal performance
Is the Options Market Predicting a Spike in Gilead Sciences (GILD) Stock?
by Zacks Equity Research
Investors in Gilead Sciences Inc. (GILD) need to pay close attention to the stock based on moves in the options market lately.
Gilead (GILD) HBV Drug Vemlidy Receives European Approval
by Zacks Equity Research
Gilead Sciences (GILD) gained EU approval for Vemlidy for the treatment of chronic HBV infection.
Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment
by Madeleine Johnson
After President-elect Donald Trump said pharmaceutical companies were ???getting away with murder,??? in how much they charge the government for medicines.
The Zacks Analyst Blog Highlights: Gilead Sciences, Pepsi, United Parcel Services, Twitter and Stanley Black & Decker
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pepsi, United Parcel Services, Twitter and Stanley Black & Decker
Top Research Reports for Pepsi, UPS & Gilead Sciences
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Gilead Sciences (GILD), Pepsi (PEP) and United Parcel Services (UPS).